Changes in metalloproteinase and tissue inhibitor of metalloproteinase during tachycardia-induced cardiomyopathy by rapid atrial pacing in dogs

Cardiology

Volumn 106, Issue 1, 2006, Pages 22-28

  Zhong, Jing Quan ^a   Zhang, Wei ^a   Li, Yan ^a   Zhong, Ming ^a   Li, Duoling ^a   Zhang, Cheng ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Metalloproteinase; Tachycardia induced cardiomyopathy; Tissue inhibitor of metalloproteinase

Indexed keywords

GAP JUNCTION PROTEIN; GELATINASE B; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIASTOLIC BLOOD PRESSURE; DOG; ECHOCARDIOGRAPHY; ENDOPLASMIC RETICULUM; FEMALE; HEART ATRIUM PACING; HEART CATHETERIZATION; HEART DILATATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE PRESSURE; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; RELAXATION TIME; SINUS RHYTHM; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHIES; CONNEXINS; DOGS; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIA; MALE; MATRIX METALLOPROTEINASE 9; MYOCARDIUM; STROKE VOLUME; TACHYCARDIA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33745699914     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092519     Document Type: Article

References (35)

1. Umana E, Solares A, Alpert MA: Tachycardia-induced cardiomyopathy. Am J Med 2003;114:51-55.
2. Kajstura J, Zhang X, Liu Y, et al: The cellular basis of pacing-induced dilated cardiomyopathy myocyte cell loss and myocyte cellular reactive hypertrophy. Circulation 1995;92:2306-2317.
3. Spinale FG, Zellner JL, Johnson WS, et al: Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 1996;28:1591-1608.
4. Pauschinger M, Chandrasekharan K, Schultheiss HP: Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev 2004;9:21-31.
5. Fareh S, Villemaire C, Nattel S: Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation 1998;98:2202-2209.
6. Morillo CA, Klein GJ, Jones DL, Guiraudon CM: Chronic rapid atrial pacing: structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995;91:1588-1595.
7. Bednarz JE, Marcus RH, Lang RM: Technical guidelines for performing automated border detection studies. J Am Soc Echocardiogr 1995;8:293-305.
8. Mathew R, Wang J, Gewitz MH, Hintze TH, Wolin MS: Congestive heart failure alters receptor-dependent cAMP-mediated relaxation of canine pulmonary arteries. Circulation 1993;87:1722-1728.
9. Weiss JL, Frederiksen JW, Weisfeldt ML: Hemodynamic determinants of the time course of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
10. Spinale, FG, Coker ML, Heung LJ, et al: A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-1949.
11. Coker ML, Doscher MA, Thomas CV, et al: Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 1999;277:H777-H787.
12. Thomas CV, Coker ML, Zellner JL, et al: Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715.
13. Gossage AM, Braxton Hicks JA: On auricular fibrillation. Q J Med 1913;6:435-440.
14. Grogan M, Smith HC, Gersh BJ, Wood DL: Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992;69:1570-1573.
15. Van Gelder IC, Crijns HS, Blanksma PK, et al: Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993;72:560-566.
16. Rodriguez LM, Smeets JL, Xie B, et al: Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137-1141.
17. Edner M, Caidahl K, Bergfeldt L, et al: Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995;74:261-267.
18. Twidale N, McDonald T, Nave K, Seal A: Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation. Pacing Clin Electrophysiol 1998;21:641-651.
19. Morady F, Hasse C, Strickberger SA, et al: Long term follow up after radiofrequency modification of the atrioventricular node in patients with atrial fibrillation. J Am Coll Cardiol 1997;29:113-121.
20. Geelen P, Goethals M, de Bruyne B, Brugada P: A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction. Am J Cardiol 1997;80:1606-1609.
21. Brown CS, Mills RM, Conti JB, Curtis AB: Clinical improvement after atrioventricular nodal ablation for atrial fibrillation does not correlate with improved ejection fraction. Am J Cardiol 1997;80:1090-1091.
22. Spencer KT, Bednarz J, Mor-Avi V, DeCara J, Lang RM: Automated endocardial border detection and evaluation of left ventricular function from contrast-enhanced images using modified acoustic quantification. J Am Soc Echocardiogr 2002;15:777-781.
23. Goens MB, Martin GR: Acoustic quantification: a new tool for diagnostic echocardiography (review). Curr Opin Cardiol 1996;11:52-60.
24. DeCara JM, Lang RM: Interpretation of left ventricular wall motion during stress testing (review). Echocardiography 2003;20:643-658.
25. Spencer KT, Bednarz J, Mor-Avi V, DeCara J, Lang RM: Assessment of global and regional left ventricular diastolic function in hypertensive heart disease using automated border detection techniques. Echocardiography 2003;20:673-681.
26. Ducharme A, Frantz S, Aikawa M, et al: Targeted deletion of the MMP-9 gene attenuates left ventricular enlargement after myocardial infarction (abstract). Circulation 1999;100 (suppl I):54.
27. Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M: Prospective study of left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial fibrillation. Br Heart J 1995;74:261-267.
28. Weber KT, Pick R, Silver MA, et al: Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990;82:1387-1401.
29. Lu L, Smith ZG, Woessner JF, et al: Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol 2000;279:H601-H609.
30. Rohde, LE, Aikawa M, Cheng GC, et al: Echocardiography-derived left ventricular end-systolic regional wall stress and matrix remodeling after experimental myocardial infarction. J Am Coll Cardiol 1999;38:835-842.
31. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Körfer R, Figulla HR: Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002;88:525-530.
32. Weber KT, Anversa P, Armstrong PW, et al: Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 1992;20:3-16.
33. Rohde LE, Ducharme A, Arroyo LH, et al: Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 1999;99:3063-3070.
34. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al: Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999;1:337-352.
35. Li YY, Feng Y, McTiernan CF, et al: Down-regulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-1152.